

From: [REDACTED]
Sent: 25 September 2020 18:03
To: [REDACTED]
[REDACTED] SANTE PHARMACEUTICALS B5
Subject: RE: Medicines for Europe meeting request | Pharma strategy & Covid19 lessons learned + 2nd Wave pandemic preparedness

Dear [REDACTED]

I have been asked to reply to your message addressed to [REDACTED] which was forwarded to [REDACTED] in DG Health and Food Safety.

We appreciate your interest in the Pharmaceutical strategy and thank you for the documents outlining Medicines for Europe position. You had suggested a meeting but I am afraid that it is not possible for the [REDACTED] nor myself to take up the invitation.

However, the opportunity of hearing your views during the recent meeting with Commissioner Kyriakides on 14 July, as well as the during the workshop organised on 14 – 15 July and the written feedback to the open consultations is appreciated.

There will continue to be opportunities for Medicines for Europe to contribute their views as the strands of the strategy are implemented.

With kind regards,

[REDACTED]



European Commission
Health and Food Safety Directorate General (SANTE)
Unit B5 Medicines-policy, authorisation and monitoring
[REDACTED]
B-1049 Brussels, Belgium

From: [REDACTED]
Sent: Tuesday, August 4, 2020 6:13 PM
To: [REDACTED]
Cc: [REDACTED]
[REDACTED]
Subject: Medicines for Europe meeting request | Pharma strategy & Covid19 lessons learned + 2nd Wave pandemic preparedness
Importance: High

Dear [REDACTED]

As you know, Medicines for Europe represents the European off-patent medicines manufacturers. Generic, biosimilar and value added medicines are almost 70% of prescribed medicines in the European Union and are critical to equitable access and to public health, as demonstrated by our industry's role in dramatically increasing the supply of medicines for Covid-19.

I am writing to you as regard to the forthcoming publication of the pharmaceutical strategy "Timely patient access to affordable medicines" by the European Commission. Medicines for Europe believes that to deliver equitable patient access to medicines and contribute to healthcare system sustainability, the pharmaceutical strategy should prioritise sustainable economic, regulatory and industrial off patent medicines policies as well as including key lessons learned from Covid-19 pandemic.


In this regard, Medicines for Europe [REDACTED] would be honored to schedule a meeting with you (virtual either face to face), at your earliest convenience, to illustrate our key policy recommendations [REDACTED]

I take the chance to share with you a copy of the letter sent last week to the Commissioner for Health, Ms. Stella Kyriakides, as well as to the German Presidency to the European Union on the second wave pandemic preparedness. At our meeting, we believe that it would be important to have an exchange of view also on such an important issue.

Thanking you in advance for the attention that you would pose to our request, we remain at your disposal for any further information you may need.

Yours sincerely,
Giuliana Pennisi

STRONGER TOGETHER IN THE
FIGHT AGAINST COVID19



Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by

Mimecast Ltd, an innovator in Software as a Service (SaaS) for business. Providing a **safer** and **more useful** place for your human generated data. Specializing in; Security, archiving and compliance. To find out more [Click Here](#).